MDGL

MADRIGAL PHARMACEUTICALS, INC.

MDGL · CIK 1157601 · Annual (10-K) · Last 8 years

Financial Trends

Revenue$958M
20182025
Net Income−$288M
20182025
Operating CF−$190M
20182025
Free Cash Flow−$190M
20182025

Income Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Revenue$1.0B$0.2B$0.0B—$0.0B$0.0B——
Cost of Revenue—$0.0B——————
Gross Profit————————
R&D Expense————————
SG&A Expense$0.8B$0.4B——————
Operating Income$-0.3B$-0.5B$-0.1B$-0.1B$-0.1B$-0.1B$-0.0B$-0.0B
Net Income$-0.3B$-0.5B$-0.1B$-0.1B$-0.1B$-0.1B$-0.0B$-0.0B
EPS (Basic)$-12.85$-21.90$-5.68$-4.98————
EPS (Diluted)$-12.85$-21.90$-5.68$-4.98————

Balance Sheet

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Total Assets$1.3B$1.0B$0.6B$0.4B$0.3B$0.3B$0.4B$0.5B
Current Assets$1.2B$1.0B$0.6B$0.4B$0.3B$0.3B$0.4B$0.5B
Cash & Equivalents$0.2B$0.1B$0.1B$0.3B$0.0B$0.1B$0.0B$0.1B
Total Liabilities$0.7B$0.3B$0.2B$0.2B$0.1B$0.0B$0.0B$0.0B
Current Liabilities$0.3B$0.2B$0.1B$0.1B$0.1B$0.0B$0.0B$0.0B
Stockholders' Equity$0.6B$0.8B$0.4B$0.2B$0.2B$0.2B$0.4B$0.5B

Cash Flow Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Operating Cash Flow$-0.2B$-0.5B$-0.3B$-0.2B$-0.2B$-0.2B$-0.0B$-0.0B
Investing Cash Flow$0.0B$-0.3B$-0.5B$0.2B$-0.0B$0.2B$0.0B$-0.4B
Capital Expenditures$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Financing Cash Flow$0.3B$0.7B$0.6B$0.3B$0.2B$0.0B$0.0B$0.3B
← Companies